Wegovy 0.25mg: the starting dose explained

The myth: "0.25mg isn't working, I need a higher dose now"

This is a question our prescribers hear most weeks, and it reflects a very reasonable frustration. You start Wegovy, you expect results, and a month in the scales have barely moved. The instinct is to push for more. But that frustration is based on a misread of what 0.25mg is for.

The licensed schedule (confirmed in the Wegovy prescribing information and summarised on the NHS semaglutide medicines page) begins at 0.25mg for precisely four weeks. This is a tolerability step. Its job is to introduce semaglutide to your system slowly enough that the GI side effects (nausea in particular) are manageable rather than overwhelming. If you want a closer look at what to expect from this opening stage, our guide to starting semaglutide at the 0.25mg dose covers the detail. At 0.25mg, the appetite suppression is mild and weight loss, if it happens at all, is modest. That is by design.

The therapeutic doses begin at 0.5mg and build through 1.0mg, 1.7mg, and 2.4mg, each held for around four weeks before the next increase, assuming you are tolerating the current level well. The 2.4mg weekly injection is where the evidence base for meaningful weight reduction sits. The STEP 1 trial, published in the New England Journal of Medicine, showed an average weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose.

Rushing the schedule does not speed up results. It makes side effects harder to bear and raises the chance of having to step back down. Patience at 0.25mg is part of the clinical plan, not a gap in it.

What semaglutide is actually doing at 0.25mg

Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone that signals fullness to the brain, slows the rate at which food leaves the stomach, and influences insulin secretion. These effects are present at 0.25mg, just not yet at a level that produces significant appetite suppression for most people.

The slow titration matters because the GI tract is sensitive to changes in gastric emptying speed. Introduce the effect too quickly and the result is nausea, vomiting, and sometimes diarrhoea severe enough to abandon treatment entirely. Starting at 0.25mg keeps those effects at a level most people can work with, often mild nausea in the first day or two after injection, settling as the week goes on.

Some people do notice reduced appetite even at 0.25mg. A smaller number notice next to nothing. Both experiences are normal. Neither predicts how well the medicine will work at therapeutic doses. You can read a broader overview of how Wegovy works and what the evidence shows if you want to understand the mechanism in more detail.

Storage follows standard Wegovy rules: refrigerate at 2–8°C and consult your Patient Information Leaflet for the permitted room-temperature window before use.

Side effects at the 0.25mg starting dose

The most commonly reported side effects of semaglutide are gastrointestinal, and the 0.25mg dose is specifically calibrated to keep them mild. Nausea is the most frequently cited. Loose stools, constipation, indigestion, and burping are also reported. Most people find these are strongest in the first 24–48 hours after each injection and ease off through the week.

Eating smaller portions, staying well hydrated, and avoiding very fatty or spicy food around injection day are the practical adjustments that tend to help most. These are not official medical instructions, your prescriber and the Patient Information Leaflet are your definitive source for managing side effects.

Serious reactions are uncommon but worth knowing about. Seek medical help promptly if you experience severe abdominal pain that extends to the back, signs of an allergic reaction, or symptoms of significant dehydration from persistent vomiting or diarrhoea. You can report suspected side effects directly to the MHRA through the Yellow Card scheme.

Wegovy carries a Black Triangle (▼) designation, which means it is under additional monitoring by the MHRA. This does not mean it is less safe than other licensed medicines, it means post-market data collection is ongoing and reporting is encouraged.

Who the 0.25mg dose applies to, and how the prescription route works

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 and above where at least one weight-related condition is present, for example, high blood pressure, type 2 diabetes, or high cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The 0.25mg dose applies to everyone starting Wegovy; it is not adjusted for weight or BMI.

The titration schedule is prescribed and overseen by a clinician. Decisions about when to move up, whether to hold a dose for longer, or whether to pause treatment belong to the prescriber, not to a self-managed plan. If you are considering the cost of private Wegovy treatment, it is worth understanding that a legitimate prescription service includes clinical oversight at every stage of the schedule, not just at the start.

If you are trying to understand whether your own results at 0.25mg are typical, the page on whether the 0.25mg dose is effective addresses that directly. For context on semaglutide as a medicine more broadly, including its licensed uses, there is a fuller overview available. Patients who are partway through the titration schedule and want to understand what comes next may also find our information on moving to the Wegovy 0.75mg dose useful.

If you are curious whether Wegovy could be suitable for you, a free consultation with a GPhC-registered prescriber is the practical next step. You can check your eligibility without commitment.